Business Context and Reporting Period
This Form 8-K is filed by FibroGen, Inc. (not Kyntra Bio, Inc., as indicated in the metadata) on September 12, 2024. The report addresses a regulatory notice regarding the continued listing of the company's common stock on The Nasdaq Global Select Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the listing notice.
- Stock Price Deficiency: The closing bid price of common stock was below $1.00 per share for 30 consecutive business days.
- Compliance Status: The company currently meets all other initial listing standards, including the market value of publicly held shares.
Material Changes
The material change reported is the receipt of a notification from the Nasdaq Listing Qualifications Staff on September 12, 2024, citing a failure to satisfy the minimum closing bid price requirement under Nasdaq listing rule 5450(a)(1). This notification has no immediate effect on the listing status.
Outlook, Risks, and Management Commentary
Compliance Timeline: FibroGen has 180 calendar days, until March 11, 2025, to regain compliance. To do so, the stock must close at or above $1.00 per share for at least ten consecutive business days before the deadline.
Contingencies and Risks:
- If compliance is not achieved by March 11, 2025, the company may be eligible for an additional 180-day period if it meets other listing standards and notifies Nasdaq of its intent to cure, potentially via a reverse stock split.
- If the company fails to cure the deficiency or does not meet other listing standards, Nasdaq may issue a delisting notice.
- The company retains the right to appeal any delisting determination to a Hearings Panel.
Management Action: Management intends to actively monitor the stock price and evaluate available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of FibroGen (FGEN) stock relative to the $1.00 threshold.
- Monitor for any announcements regarding a potential reverse stock split to regain compliance.
- Track the company's progress toward achieving ten consecutive days of trading above $1.00 before the March 11, 2025 deadline.
- Review subsequent filings for any updates on the market value of publicly held shares or other listing standards.